Long-term follow-up high-dose chemotherapy (drug-only program) followed by autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas
- PMID: 15989704
- DOI: 10.3816/clm.2005.n.024
Long-term follow-up high-dose chemotherapy (drug-only program) followed by autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas
Abstract
Purpose: To investigate the feasibility of high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) for aggressive non-Hodgkin's lymphoma (NHL), we conducted HDCT with ASCT using a drug-only protocol without total body irradiation. Previously untreated and treated adult patients with aggressive lymphoma were enrolled onto this study. For the HDCT protocol, we developed the AECC regimen, a drug-only regimen consisting of etoposide, carboplatin, cyclophosphamide, and nimustine (ie, ACNU). Mobilized peripheral blood stem cells were used mainly as a source for ASCT and were used based on collection rates of CD34 cells.
Patients and methods: Fifty-six patients were enrolled and assessed for this study. The median length of follow-up was 6.5 years, with a range of 0.2-12.5 years. Retrospective immunophenotypic examination indicated that the majority of the patients were diagnosed with B-cell lymphoma.
Results: Before HDCT, 37 patients still had disease (26 partial responses [PRs] and 11 cases of no response), and 19 patients exhibited a complete response (CR) before HDCT with ASCT. Among 56 patients, 37 (66%) exhibited a CR, including patients continuing their first CR and those experiencing a second or further CR, and 11 patients (19.6%) exhibited PR on HDCT with ASCT. Outcomes of patients without CR were significantly poorer than those of the patients with CR, and 7-year overall survival rates of patients with and without CR were 63% and 27.2%, respectively. No patients developed a second malignancy, including leukemia or myelodysplastic syndrome.
Conclusions: High-dose chemotherapy followed by ASCT is one of the available consolidation therapies for aggressive NHL, and additional involved-field irradiation could play a role in the management of patients with NHL who do not exhibit a CR after treatment with HDCT containing a drug-only program.
Similar articles
-
Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index.Ann Oncol. 2004 Sep;15(9):1419-24. doi: 10.1093/annonc/mdh353. Ann Oncol. 2004. PMID: 15319249 Clinical Trial.
-
Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?J Clin Oncol. 2000 Jan;18(2):332-9. doi: 10.1200/JCO.2000.18.2.332. J Clin Oncol. 2000. PMID: 10637247
-
Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.J Clin Oncol. 2005 Jun 1;23(16):3793-801. doi: 10.1200/JCO.2005.07.039. Epub 2005 Apr 4. J Clin Oncol. 2005. PMID: 15809447 Clinical Trial.
-
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review.
-
Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.Semin Oncol. 2002 Feb;29(1 Suppl 2):56-69. Semin Oncol. 2002. PMID: 11842390 Review.
Cited by
-
Feasibility and efficacy of high-dose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin's lymphoma.Int J Hematol. 2006 Aug;84(2):174-81. doi: 10.1532/IJH97.06023. Int J Hematol. 2006. PMID: 16926142 Clinical Trial.
-
Age-Related Disease Risks in Younger versus Older B-Cell Non-Hodgkin's Lymphoma Survivors.Cancer Epidemiol Biomarkers Prev. 2021 Dec;30(12):2268-2277. doi: 10.1158/1055-9965.EPI-21-0190. Epub 2021 Nov 3. Cancer Epidemiol Biomarkers Prev. 2021. PMID: 34732401 Free PMC article.
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Research Materials